Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
CYTK - they present again this afternoon @3pm. Are they doing the same one they did Last weekend and Monday?
Cytokinetics to Present at the Deutsche Bank BIOFest Conference
7:30 am ET 12/14/2010- Market Wire
SOUTH SAN FRANCISCO, CA -- (MARKET WIRE) -- 12/14/10 -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that Robert I. Blum, President and Chief Executive Officer, is scheduled to present a corporate update at the Deutsche Bank BIOFest Conference on Tuesday, December 14th at 3:00 p.m. Eastern Standard Time at the Four Seasons Hotel, Boston Massachusetts.
About Cytokinetics
Cytokinetics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions. Cytokinetics' lead drug candidate from its cardiac muscle contractility program, omecamtiv mecarbil (formerly CK-1827452), is in clinical development for the potential treatment of heart failure. Amgen Inc. holds an exclusive license worldwide (excluding Japan) to develop and commercialize omecamtiv mecarbil and related compounds, subject to Cytokinetics' specified development and commercialization participation rights. Cytokinetics is independently developing CK-2017357, a skeletal muscle activator, as a potential treatment for diseases and conditions associated with aging, muscle wasting or neuromuscular dysfunction. CK-2017357 is currently the subject of a Phase IIa clinical trials program and has been granted orphan-drug designation by the U.S. Food and Drug Administration for the potential treatment of amyotrophic lateral sclerosis. Cytokinetics is also conducting non-clinical development of compounds that inhibit smooth muscle contractility and which may be useful as potential treatments for diseases and conditions associated with excessive smooth muscle contraction, such as systemic hypertension or bronchoconstriction. In addition, prior Cytokinetics' research generated three anti-cancer drug candidates that have progressed into clinical development: ispinesib, SB-743921 and GSK-923295. All of these drug candidates and potential drug candidates have arisen from Cytokinetics' research activities and are directed towards the cytoskeleton. The cytoskeleton is a complex biological infrastructure that plays a fundamental role within every human cell. Additional information about Cytokinetics can be obtained at www.cytokinetics.com.
EXEL - Go Figya...
After their ovarian cancer news in mid Nov they've been on my radar, then I took them off any watch list because they announced a 65% Reduction in force. Every RIF I've seen was NOT good news but EXEL has gone gangbusters...go figya
They do have some prostate cancer efforts underway that seem to be getting all their focus now...anybody else know anything about them?
tia
S
CTYK - This is good news, I added, this is a share grab from weak hands imho...
The report of findings is still important in that this interim presentation shows progress to validate continued testing. There's still a second milestone event for eoy'10 also
While i'm disappointed we didn't get and hold $3, still in the green here and adding to raise avg entry
CTYK popped like a coiled spring @ close $^)
DVAX perking into the close. Anyone familiar w/ their flu vaccine efforts. NVAX usually moves in sympathy
CTYK eod volume spike, last minute share grab...
it's been held down last 2 days for accumulation imho
DCTH breakout, volume spike
IMUC surge continues, nice volume, had presentation yday that must have gone well, no news
fm earlier post...
ImmunoCellular Therapeutics' Chief Executive Officer to Present at Prestigious Cancer Stem Cell Conference
10:18 am ET 12/08/2010- Business Wire
LOS ANGELES--(BUSINESS WIRE)--Dec. 8, 2010-- ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC), a biotechnology company focused on the development of novel immune-based cancer therapies, announced today that Manish Singh Ph.D., the company's President and Chief Executive Officer, will present at the World Cancer Stem Cell Summit at the Boston Park Plaza Hotel & Towers in Boston, MA. on Thursday, December 9th at 2:05 p.m.
DVAX sneaking up steadily, nyh breakout >2.34
IMUC spiking on 3X avg vol ahead of presentation this afternoon. Could make a nice break >1.43, it's hod
ImmunoCellular Therapeutics' Chief Executive Officer to Present at Prestigious Cancer Stem Cell Conference
10:18 am ET 12/08/2010- Business Wire
LOS ANGELES--(BUSINESS WIRE)--Dec. 8, 2010-- ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC), a biotechnology company focused on the development of novel immune-based cancer therapies, announced today that Manish Singh Ph.D., the company's President and Chief Executive Officer, will present at the World Cancer Stem Cell Summit at the Boston Park Plaza Hotel & Towers in Boston, MA. on Thursday, December 9th at 2:05 p.m.
The World CSC Summit focuses on overcoming the challenges faced in utilizing cancer stem cell therapies, exploring the very latest lines of research and the move into clinical trials. The event features innovative case studies and cutting-edge practical insights, bringing together thought leaders from all areas involved in cancer stem cell study. For more information about the World Cancer Stem Cell Conference, please visit www.csc-summit.com.
In short Yes. $2.70 = 200SMA also, breakout would see $3 next w/ a speed bump @ $2.85 BUT...
Key to this is that most are not into this as a chart play! CYTK just gets warmed up @ $3 w/ good news.
ethically, yes. politically, no
can't wait to go people watching in Walmart to gaze at those lined up to pick up their weight loss Rx
OREX - fda advisory panel votes 11-8 to back new trial after approval of contrave
VVUS on a tear - sees upside on poitive OREX vote
OREX fda advisory panel votes 11-8 to back new trial after approval of contrave...please note that this is just one of the votes/issues in front of panel
PL1 - I think you'll agree this is how to get to heaven the hard way...
http://www.liveleak.com/mp53/player.swf?config=http://www.liveleak.com/mp53/player_config.php?token=07b_1284580365%26embed=1
So this is what it's like to ride a trade in the biotech world...This is an amazing video!
http://www.liveleak.com/mp53/player.swf?config=http://www.liveleak.com/mp53/player_config.php?token=07b_1284580365%26embed=1
CYTK - Canaccord maintains BUY but lowers tgt to $6 fm $7
Speaking of which AEZS making a break $^)
OREX - FDA reviewers say diet pill works...BUT cite safety issues ahead of advisors mtg this Tuesday
IMUC - started small position on 2.5X avg vol, perky chart action testing breakout
RTN - What are your first impressions?
My first thought was a marriage of a Iplex w/ a delivery system
tia
S
ICGN gets a $1 Million milestone payment...
and their mktcap nearly doubles???? hmmm
AEZS breaks out @ $1.43, nice big volume spike ahead of 12/4 presentation
for more see... http://seekingalpha.com/article/237174-soon-to-be-released-data-poised-to-propel-aeterna-zentaris-value
Sold AMRN, Bot AEZS
Congrats & thx for AMRN
glta
s
AEZS - Buy rating $5.50 tgt by McNicoll, Lewis & Vlak
wow, I meant 2:15pm had no idea it's headed to $2.15
keep in mind they just filed a shelf so a secondary's likely coming
hope folks were nimble on this one today and didn't get stuck
glta
ASTM resumes @ 2:15
ASTM halted pending results for phase 2b RESTORE-CLI trial
What are expectations for Monday? news event? tia
ALXA nice move w/ vol.
VTG up 16%
VTG - One of xela's Friday Stocks to Ponder off to nice start.
FBR Capital Reiterates an 'Outperform' on Vantage Drilling (VTG); Financing Complete; Still an Acquisition Target
7:26 AM ET - StreetInsider
FBR Capital reiterates an 'Outperform' rating on Vantage Drilling Company, lowers price target from $2.20 to $1.90. FBR analyst says, "After the close last night, Vantage announced the pricing of its $1 billion debt offering at 11.5%, offered at 96% of par, and the pricing of $50 million of equity at $1.10 per share.
VTG - One of xela's Friday Stocks to Ponder off to nice start.
FBR Capital Reiterates an 'Outperform' on Vantage Drilling (VTG); Financing Complete; Still an Acquisition Target
7:26 AM ET - StreetInsider
FBR Capital reiterates an 'Outperform' rating on Vantage Drilling Company, lowers price target from $2.20 to $1.90. FBR analyst says, "After the close last night, Vantage announced the pricing of its $1 billion debt offering at 11.5%, offered at 96% of par, and the pricing of $50 million of equity at $1.10 per share.
MNTA out of control...$25 jeeesh
VTG - xela, kg question...
they announced a $50M offeringthis week, what impact will that have iyho
thx
S
ALXA - Alexza to Announce 2010 Second Quarter Financial Results on Monday, July 26, 2010
Preannouncement? Weren't they scheduled for 8/5?
ALXA - Alexza to Announce 2010 Second Quarter Financial Results on Monday, July 26, 2010
Preannouncement? Weren't they scheduled for 8/5?
ALXA - Alexza to Announce 2010 Second Quarter Financial Results on Monday, July 26, 2010
Preannouncement? Weren't they scheduled for 8/5?
K, the guy "reporting" the story is Richard C. Hoagland, a regular on the radio show Coast to Coast w/ George Noory... http://www.coasttocoastam.com/ , a sounding board for conspirocy theorists, ufo geeks and psychics. While I don't question mr. simmons credentials and theory, Hoagland and Noory have serious credibility issues. I have a pretty wacked out cousin who produces a competing radiostation and they won't have anything to do w/ Hoagland.
There are several versions of the vid floating on YouTube.
While it's food for thought and I hope to god they're wrong I still am not convinced.